JT Koerber

My group seeks to discover and engineer novel antibody solutions as biological tools and next-generation therapeutics. We focus mainly on two areas: complex membrane proteins and engineered antibody formats.

1. Many complex membrane proteins, such as multi-transmembrane or disulfide-rich proteins, are often mutated or dysregulated in human disease, and as a whole, comprise a largely untapped target class. My group works in collaboration with structural biology and other biology groups to develop new technologies to advance therapeutic development in this area and unlock this challenging target space.
2. Many biological barriers exist that prevent efficient drug delivery to a tissue of interest. We work to engineer novel antibody formats capable of overcoming these barriers.

• University of California, Berkeley, PhD – 2008
• University of Illinois, Urbana-Champaign, B.S. – 2003

• Roche Key Contributor – 2017
• Roche Key Contributor – 2016
• Life Sciences Research Foundational Postdoctoral Fellowship – 2009
• National Science Foundation Graduate Fellowship – 2003